Trial Profile

A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valbenazine (Primary)
Indications Drug-induced dyskinesia
Focus Adverse reactions; Registrational
Acronyms Kinect 4
Sponsors Neurocrine Biosciences

Most Recent Events

20 Mar 2025 According to a Neurocrine Biosciences media release, new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily valbenazine capsules was presented at the 2025 Psychiatry Update Conference in Chicago.
21 May 2024 According to an Neurocrine Biosciences media release, results of post hoc analysis(n=103) from KINECT-4 study published in the Journal of Clinical Psychopharmacology..
21 May 2024 Results published in the Neurocrine Biosciences Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com